Sanofi’s pediatric hexavalent vaccine approved by U.S. FDA

PARIS (Reuters) – The U.S. Food and Drug Administration approved Sanofi’s new pediatric vaccine immunizing children against six diseases, the French pharmaceutical lab said on Wednesday.

Sanofi developed the new vaccine, dubbed Vaxelis, in partnership with Merck.

Vaxelis is designed for children aged 6 weeks to 4 years old and is designed to keep them from contracting diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to haemophilus influenza type B.

Sanofi and Merck are now working on the production and supply of Vaxelis aiming to make it available on the market in 2020 or later.